ABCAM PLC Director/PDMR Shareholding (1339K)

TIDMABC

RNS Number : 1339K

ABCAM PLC

03 May 2022

For immediate release

03 May 2022

ABCAM PLC

("Abcam" or the "Company")

Director/PDMR Shareholding Notification

Cambridge, UK: Abcam plc (Nasdaq: ABCM; AIM: ABC), a global leader in the supply of life science research tools, has been notified of the following dealings in Abcam's shares by certain Directors of the Company as follows:

-- Sally W. Crawford, Non-Executive Director, purchased 13,141 American Depositary Receipts at a price of US$15.361 on Thursday 28 April 2022 and 1,859 American Depositary Receipts at a price of US$15.7165 on Friday 29 April 2022.

The notification for Ms Crawford can be found below.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                             Ms Sally W. Crawford 
      -------------------------------  -------------------------------------------------------- 
 2     Reason for the notification 
      ----------------------------------------------------------------------------------------- 
 a)    Position/status                  Non-Executive Director 
      -------------------------------  -------------------------------------------------------- 
 b)    Initial notification             Initial Notification 
        /Amendment 
      -------------------------------  -------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------------------- 
 a)    Name                             Abcam plc 
      -------------------------------  -------------------------------------------------------- 
 b)    Legal Entity Identifier          213800B9N83DSNT33F79 
      -------------------------------  -------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ----------------------------------------------------------------------------------------- 
 a)    Description of the financial     American Depositary Shares 
        instrument, type of 
        instrument 
                                         US0003802040/ABCM 
        Identification code 
      -------------------------------  -------------------------------------------------------- 
 b)    Nature of the transaction        Purchase 
      -------------------------------  -------------------------------------------------------- 
 c)    Currency                         USD 
      -------------------------------  -------------------------------------------------------- 
 d)    Price(s) and volume(s)                Price(s)                    Volume(s) 
                                       -------------------  ----------------------------------- 
   USD$15.361                                                13,141 
  --------------------------------------------------------  ----------------------------------- 
   USD$15.7165                                               1,859 
  --------------------------------------------------------  ----------------------------------- 
 e)    Aggregated information              Price(s)       Aggregated Volume(s)     Aggregated 
        Acquisition of shares                                                         Total 
        on release of award 
        Sales of shares to satisfy 
        income tax, national 
        insurance and dealing 
        charges 
      -------------------------------  ---------------  -----------------------  -------------- 
                       USD$15.4051                               15,000            $231,075.87 
  ----------------------------------------------------  -----------------------  -------------- 
 
 f)    Date of the transaction          28 and 29 April 2022 
      -------------------------------  -------------------------------------------------------- 
 g)    Place of the transaction         The Nasdaq Global Select Market 
      -------------------------------  -------------------------------------------------------- 
 
 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding award eligibility and LTIP issuance and value sufficiency under the laws of the United Kingdom, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus ("COVID-19"), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; and the important factors discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFXLFBLELXBBV

(END) Dow Jones Newswires

May 03, 2022 07:41 ET (11:41 GMT)